A Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-Vectored H5N1

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/093/31/18

Funding

  • PaxVax Incorporated: $828,067.00